中文摘要：

目的探讨星形细胞瘤组织中特异性的核基质结合区结合蛋白-1（SATB1）基因、SLC22A18蛋白的表达、与肿瘤恶性程度及两者之间的相互关系。方法选取上海交通大学医学院附属第三人民医院神经外科自2006年9月至2010年6月、武汉大学中南医院神经外科自2003年9月至2006年6月间手术切除的星形细胞瘤标本56例，其中WHO分级I级12例．Ⅱ级13例，Ⅲ级15例，Ⅳ级16例。另选10例行内减压术颅脑损伤患者的正常脑组织作为对照组。应用RT-PCR和Westernblotting分别检测各标本中SATBlmRNA和蛋白的表达，免疫组织化学法检测各标本中SLC22A18蛋白的表达，分析二者与肿瘤恶性程度及两者之间的相互关系。结果RT-PCR与Westernblotting检测显示对照组脑组织中SATB1mRNA和蛋白有少许表达，星形细胞瘤中35例表达阳性；不同级别星形细胞瘤SATBlmRNA和蛋白的阳性表达率、表达值不同，且随着肿瘤病理级别的增高，SATBlmRNA和蛋白的表达值增强，差异有统计学意义（P〈0．05）。SATB1蛋白的表达值与肿瘤的病理级别呈正相关关系（r=0．987，P=-0．000）；免疫组织化学法检测显示对照组均检测到SLC22A18表达，星形细胞瘤中19例SLC22A18表达阳性。不同级别星形细胞瘤SLC22A18的阳性表达率不同，随着肿瘤病理级别的增高．SLC22A18的阳性表达率降低，差异有统计学意义（P〈0．05）；SLC22A18表达阴性组中SATB1蛋白阳性表达率（81．1%）显著高于SLC22A18表达阳性组（26.3％），差异有统计学意义（P〈0．05）。结论SATB1基因在星形细胞瘤中表达，提示该基因对星形细胞瘤发生和发展起重要作用；抑癌基因SL22AJ8的失活与SATBJ基因的表达可能在星形细胞瘤的发生中起协同作用。

英文摘要：

Objective To study the expression of special AT-rich sequence-binding protein 1 （SA TB1） gene and its relationship with SLC22A18 protein expression in astrocytoma. Methods Fifty-six patients with astrocytomas （12 with grade I, 13 with grade Ⅱ, 15 with grade Ⅲ, and 16 with grade IV）, performed surgical excision in our hospitals from September 2006 to June 2010 and fi＇om September 2003 to June 2006, were chosen in our study; another 10 brain tissues from patients performed decompression operation resulting from cerebral hernia were selected as the controls. RT-PCR and Western blotting were used to detect the mRNA and protein expressions of SA TB1. The SLC22A18 protein expression was detected by immunohistochemical assay. The relations between SLC22A18 expressions and SA TB1 levels, and these two and the degree of malignancy were analyzed. ResultsRT-PCR and Western blotting revealed that positive mRNA and protein expressions were noted in 35 patients with astrocytomas; the mRNA and protein expression rate and value ofSA TB1 in the astrocytoma tissues were significantly different among different grades of tumors （P〈0.05）; the higher the malignancy grade, the higher mRNA and protein expression rate and value ofSA TB1; the protein expression value of SA TB1 had a positive correlation with the malignancy grade of tumors （1-=0.987, P=-0.000）. And a few expressions of SA TB1 mRNA and protein were found in the tissues of controls. Immunohistochemical assay indicated that positive protein expression of SLC22A18 was noted in 19 astrocytoma tissues, and the protein expression rate of SLC22A18 in the astrocytoma tissues was significantly different among different grades of tumors （P〈0.05）; the higher the malignancy grade, the lower expression of SLC22A18. And the protein expression of SLC22A18 was found in all the tissues of controls. The SA TB1 expression rate in the tissues with negative SLC22A18 expression （81.1%） was significantly higher than that in the tissues with positive SLC22A18 expr